ABBV vs TERN

AbbVie Inc. (ABBV) is a well-established mega-cap pharmaceutical company with a robust product portfolio, strong financial health, and a leading position in key therapeutic areas. It excels as a stable dividend payer and a defensive holding. However, its fundamental characteristics, including its immense market capitalization ($397.29B), the mature nature of the pharmaceutical industry, high R&D c...

Score Change Explanation: The drastic score reduction from 70/100 to 10/100 is due to the fundamental change in Terns Pharmaceuticals' investment profile. On March 25, 2026, Merck agreed to acquire TERN for $53/share cash. This acquisition eliminates TERN's independent 10x growth potential, which was the core thesis of the previous analysis. For existing shareholders, the upside is now capped at t...